Key result
Newly diagnosed patients with chronic lymphocytic leukemia had significantly higher fold change expression of SEMA3A (7.58 vs 1.01) and SEMA4D (3.20 vs 1.00) compared to healthy subjects.
Why the study?
Semaphorins play prominent roles in vascular development, tumor growth, and immune responses across cancers, but their expression in chronic lymphocytic leukemia had not been studied.
Are the expression levels of SEMA3A, SEMA4A, and SEMA4D elevated in the peripheral blood of newly diagnosed patients with chronic lymphocytic leukemia compared to healthy controls?
Case-Control (n=60)
No
Are the expression levels of SEMA3A, SEMA4A, and SEMA4D elevated in the peripheral blood of newly diagnosed patients with chronic lymphocytic leukemia compared to healthy controls?
SEMA3A and SEMA4D expression levels are significantly elevated in the peripheral blood of newly diagnosed CLL patients, suggesting a potential role in the disease's pathogenesis.
Background: Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses. Semaphorins have different roles in various kinds of cancers, but there is no study concerning their expression in the chronic lymphocytic leukemia (CLL). This study aimed to assess the SEMA3A, SEMA4A and SEMA4D expression in patients with CLL. Materials and Methods: Peripheral blood specimens were collected from 30 newly-diagnosed untreated patients with CLL and 30 healthy subjects as a control group. The SEMA3A, SEMA4A and SEMA4D expression was determined by real-time PCR method. Results: The fold change expression of SEMA3A and SEMA4D was 7.58 ± 2.66 and 3.20 ± 0.99 in patients with CLL, and was 1.01 ± 0.31 and 1.00 ± 0.27 in healthy subjects, respectively. The CLL patients expressed higher amounts of SEMA3A and SEMA4D in comparison with healthy subjects (P<0.02 and P<0.03, respectively). The fold change expression of SEMA3A in patients with stage II (11.12 ± 5.35) was also higher than patients with stage I (4.49 ± 1.61, P<0.05). No significant difference was also observed in the expression of SEMA4A and SEMA4D between patients with stage I and stage II CLL. In both CLL and control groups, the fold change expression of SEMA3A was higher in men than in women (P<0.03 and P<0.02, respectively). Conclusion: The results of the study indicated elevated expression of the SEMA3A and SEMA4D in patients with CLL. The SEMA3A expression was influenced by tumor stage and gender of participants.
No takes yet. Share an insight, caveat, or question.
Parsa et al. (2019) conducted a case-control in Chronic Lymphocytic Leukemia (n=60). SEMA3A and SEMA4D expression vs. Healthy subjects was evaluated on SEMA3A fold change expression (p=<0.02). Newly diagnosed patients with chronic lymphocytic leukemia had significantly higher fold change expression of SEMA3A (7.58 vs 1.01) and SEMA4D (3.20 vs 1.00) compared to healthy subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: